Clinical trials: Chidamide
Metastatic Colorectal Cancer
Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)
This study is designed as an open-label, dose-escalation manner to determine the MFD of chidamide in combination with celecoxib in patients with advanced mCRC.
- Trial name
- NCT05281276
- Testing
- chidamide, celecoxib
- Where
- Taiwan
- Volunteers
- 9 people
- Sponsor
- Taipei Medical University Shuang Ho Hospital
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma
This is a phase 1b/2a, open-label trial to evaluate the safety, pharmacokinetics, and preliminary efficacy of lisaftoclax in combination with chidamide and rituximab in patients with relapsed or refractory diffuse large B-cell…
- Trial name
- NCT07601607
- Testing
- Lisaftoclax, Chidamide, rituximab
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Sun Yat-sen University
Newly Diagnosed Acute Myeloid Leukemia (AML), Elderly Patients
Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia
This study is a multicenter, prospective, randomized, controlled clinical trial, observing the efficacy and safety of the CACAG+Venetoclax regimen (Chidamide + Azacitidine + Aclarubicin + Cytarabine + Recombinant Human…
- Trial name
- NCT07514936
- Testing
- the standard "3+7" regimen, Azacytidine; Cytarabine; Aclacinomycin; Chidamide; Venetoclax; Granulocyte
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Chinese PLA General Hospital
Relapsed or Refractory Peripheral T-cell Lymphoma
Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
The purpose of this open label,single arm,phase Ⅱ clinical trail is to determine the safety and efficacy of Chidamide combination with lenalidomide for relapsed or refractory peripheral T-cell lymphoma.
- Trial name
- NCT04329130
- Testing
- Chidamide, Lenalidomide
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Sun Yat-sen University
Lymphoma
Radiotherapy Combined With GDP With or Without Chidamide in Stage I/II Extranodal Nasal NK/T-cell Lymphoma
Currently, combined chemotherapy (CT) and radiation (RT) is recognized as the standard treatment for high-risk early-stage NKTCL.
- Trial name
- NCT04511351
- Testing
- Chidamide
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Chinese Academy of Medical Sciences
AML
Efficacy and Safety of Chidamide in CBF Leukemia
In this open-label, randomized, prospective clinical trial, CBF acute myeloid leukemia (AML) patients who have reached CR are randomised into two groups and receive high-dose cytarabine (HDAC) or high-dose cytarabine plus…
- Trial name
- NCT03031262
- Testing
- Cytarabine, Chidamide
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Myeloid Leukemia
Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is highly heterogeneous, the efficacy of the individual varies greatly, and the risk of recurrence is high.
- Trial name
- NCT05330364
- Testing
- Chidamide, Cladribine
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Ge Zheng
Angioimmunoblastic T-cell Lymphoma
Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma
This is a multicenter prospective single arm phase II study. The purpose of this study is to evaluate the safety and efficiency of azacytidine combined with chidamide in the treatment of relapsed/refractory angioimmunoblastic…
- Trial name
- NCT05179213
- Testing
- Azacitidine, Chidamide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
HIV (Human Immunodeficiency Virus)
A Safety and Efficacy Trial of Chidamide Combined With NKG2D CAR-NK Cell Therapy for Reducing the HIV Viral Reservoir
This study aims to investigate the safety and preliminary efficacy of an innovative therapeutic strategy combining chidamide with NKG2D-directed chimeric antigen receptor natural killer (CAR-NK) cells in individuals living with…
- Trial name
- NCT07577986
- Testing
- Chidamide Combined with NKG2D CAR-NK Cell Therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
New Diagnosed Angioimmunoblastic T-Cell Lymphoma
Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL
Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive lymphoma. At present, the treatment of new diagnosed AITL has limited efficacy and a high recurrence rate.
- Trial name
- NCT07168317
- Testing
- tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Newly Diagnosed Peripheral T-cell Lymphoma
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma
Peripheral T-cell lymphoma (PTCL) is a highly heterogeneous and aggressive non-Hodgkin's lymphoma. The incidence rate of PTCL in China is much higher than the global average, and there is no unified standard treatment for initial…
- Trial name
- NCT05896813
- Testing
- CMOP+Chidamide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Safety and Efficacy
Study of Chidamide for Steroid-resistant/Steroid-dependent Severe cGVHD
Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is one of the most important and effective methods for the treatment of hematologic malignancies.Chronic graft-versus-host disease (cGVHD) is a serious complication…
- Trial name
- NCT05140616
- Testing
- Chidamide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Diffuse Large B Cell Lymphoma (DLBCL), Double Expressor Lymphoma
Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor Lymphoma
This study is trying to explore the mechanism of R-CHOP regimen or tucidinostat plus R-CHOP (CR-CHOP) regimen in the treatment of BCL2/MYC protein double expressor lymphoma.
- Trial name
- DEL Biomarker (NCT06652152)
- Volunteers
- 400 people
- Sponsor
- Ruijin Hospital
Peripheral T-cell Lymphoma Targeted Therapy
AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH
This study is an open label, multicenter study. Subjects are randomized at a 1:1 ratio to receive either (arm A) azacitidine administered IH at day 1-5 and chidamide admistered twice a week for two weeks in combination with…
- Trial name
- NCT05678933
- Testing
- Azacitidine, Chidamide, Cyclophosphamide
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Diffuse Large B-cell Lymphoma
Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma
A phase II，single arm，open-label study to assess Maintenance Therapy of Chidamide in Patients With Hepatitis B Virus（HBV）Positive Diffuse Large B-cell Lymphoma with complete response after completion of prior chemotherapy
- Trial name
- NCT04661943
- Testing
- Tucidinostat
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ou Bai, MD/PHD
Leukemia, Acute, Leukemia, T Cell
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL
ETP-ALL is a recently recognized high-risk subgroup and the optimal therapeutic approaches are poorly characterized. Based on the pediatric-inspired, PEG-L-asparaginase-intensified and MRD-directed PDT-ALL-2016 protocol, this…
- Conditions
- Leukemia, Acute, Leukemia, T Cell, Leukemia, Lymphoblastic
- Trial name
- NCT03553238
- Testing
- Chidamide, Dexamethasone, vincristine
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Diffuse Large B-Cell Lymphoma (DLBCL)
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
A Single-Arm, Open-Label, Multicenter Phase II Trial of CRP Regimen (Chidamide, Rituximab, Polatuzumab Vedotin) in Treating Elderly Patients with Previously Untreated Double-Positive Diffuse Large B-Cell Lymphoma
- Trial name
- NCT07397832
- Testing
- Chidamide, Rituximab, Polatuzumab Vedotin
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Angioimmunoblastic T-cell Lymphoma
Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma
This is a single-arm, open-label phase 2study of Chidamide in combination with CHOP in the treatment of subjects with untreated angioimmunoblastic T cell lymphoma.
- Trial name
- NCT03853044
- Testing
- Chidamide, Cyclophosphamide, Doxorubicin
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Ruijin Hospital
Peripheral T-Cell Lymphoma
The Efficacy of CAPCT in Patients With PTCL
This study is a multicenter, single-arm, non-randomized, open-label trial designed to evaluate the efficacy and safety of chidamide and azacitidine in combination with prednisone, cyclophosphamide, and thalidomide (CAPCT regimen)…
- Trial name
- NCT07746245
- Testing
- Chidamide, Azacitidine (AZA), Prednisone
- Where
- China
- Volunteers
- 58 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Cutaneous T-cell Lymphoma
Phase I/II Study of Linperlisib Plus Chidamide for R/R Cutaneous T-cell Lymphoma: a Prospective, Single-center Study
HDAC inhibitor chidamide and PI3K inhibitor linperlisib has shown clinical activity as mono therapy in PTCL. The combination of duvelisib and romidepsin is highly active against relapsed and refractory T-cell lymphomas including…
- Trial name
- NCT06037239
- Testing
- Linperlisib in combined with Chidamide
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Peking Union Medical College Hospital